Capital International, Inc. Gracell Biotechnologies Inc. Transaction History

Capital International, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.08 - $3.96 $153,013 - $291,313	-73,564 Reduced 2.44%	2,942,807 $6.77 Million
Q3 2022 Nov 14, 2022	BUY	$2.08 - $5.15 $47,166 - $116,781	22,676 Added 0.76%	3,016,371 $9.71 Million
Q2 2022 Aug 15, 2022	BUY	$1.95 - $5.5 $1.28 Million - $3.62 Million	658,219 Added 28.18%	2,993,695 $16.5 Million
Q1 2022 May 16, 2022	BUY	$1.83 - $5.52 $1.07 Million - $3.23 Million	584,769 Added 33.4%	2,335,476 $5.44 Million
Q4 2021 Feb 14, 2022	BUY	$5.65 - $14.9 $3.33 Million - $8.79 Million	589,816 Added 50.81%	1,750,707 $10.6 Million

Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $1.62 Million - $2.43 Million	163,653 Added 16.41%	1,160,891 $16.1 Million
Q2 2021 Aug 16, 2021	BUY	$9.75 - $18.42 $1.12 Million - $2.11 Million	114,470 Added 12.97%	997,238 $13 Million
Q1 2021 May 14, 2021	BUY	$14.7 - $30.57 $13 Million - $27 Million	882,768 New	882,768 $13.6 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital International, Inc. with notifications on news.